World leader in cardiac surgery, interventional, and neurovascular products selects clinivation Global xi to manage its medical products approvals and submissions worldwide.
Framingham, MA, March 19, 2007 – clinivation, Inc. announced today that Terumo Cardiovascular Systems, subsidiary of Terumo Corporation (Tokyo Stock Exchange: 4543), has selected the clinivation Global Enterprise Solution for Market Clearance Management Market Clearance Management solution.
“Terumo Corporation’s products and services are synonymous with quality and performance in hospitals around the world,” said Joseph Kozikowski, M.D., clinivation’s Chief Executive Officer. “We are delighted Terumo’s management has selected clinivation Global xi to help impact market clearance operations to better achieve sales and marketing objectives,” he continued.
Clinivation Global xi software enables medical device companies to sell more products to more countries faster and easier than ever before. Clinivation Global xi is the first complete solution targeted at automating the business processes for market clearance operations worldwide.
About Terumo Cardiovascular Systems
Terumo Cardiovascular Systems Corporation manufactures and markets products for the global cardiac surgery, interventional and neurovascular markets. It is headquartered in Ann Arbor, Michigan with manufacturing operations in Ann Arbor, as well as Elkton, Maryland; Ashland, Massachusetts; and Tustin, California. It is one of several subsidiaries of Terumo Corporation of Japan focused exclusively on the cardiac and vascular markets, including Vascutek-Terumo, developer of vascular grafts; and Terumo Heart Inc., developer of a ventricular assist device.
For further information, visit www.terumo-cvs.com.